

# B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Review report

### To Board of Directors of Alkem Laboratories Limited

We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Alkem Laboratories Limited ('the Company') and its subsidiaries listed in Annexure I (the Company and its subsidiaries together referred to as 'the Group') for the quarter and nine months ended 31 December 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 9 February 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the interim financial results of two subsidiaries included in the unaudited consolidated financial results, whose interim financial results reflect total revenues of Rs. 2,043.0 million and Rs. 5,015.0 million for the quarter and nine months ended 31 December 2017 respectively, as considered in the unaudited consolidated financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors. Our conclusion is not modified in respect of this matter.

The unaudited consolidated financial results includes the interim financial results of sixteen subsidiaries which have not been subjected to limited review by their auditors and have been presented based on the financial information compiled by the Company's management. Interim financial results of these subsidiaries reflect total revenues of Rs. 1,266.5 million and Rs. 3,531.3 million for the quarter and nine months ended 31 December 2017 respectively, as considered in the unaudited consolidated financial results. Our conclusion on the Statement in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the unaudited financial information. In our opinion and according to the information and explanations given to us by the management, this unaudited financial information is not material to the Group. Our conclusion is not modified in respect of this matter.



B S R & Co. LLP

**Review report (*Continued*)**

**Alkem Laboratories Limited**

Based on our review conducted as above and based on the consideration of the reports of other auditors and based on the consideration of interim financial information furnished to us by the management referred to in paragraph above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For B S R & Co. LLP**

*Chartered Accountants*

Firm Registration No. 101248W/W-100022



**Sadashiv Shetty**

*Partner*

Membership No: 048648

**Mumbai**

**9 February 2018**

# Alkem Laboratories Limited

## Annexure I to the Review report

### 1. List of Subsidiaries

Sr. No.	Name of Subsidiaries
1.	ThePharmaNetwork, LLC, USA
2.	S & B Pharma Inc., USA
3.	Alkem Laboratories (NIG) Limited, Nigeria
4.	Pharmacor Pty Limited, Australia
5.	Alkem Laboratories (PTY) Ltd, South Africa
6.	Enzene Biosciences Limited, India
7.	Cachet Pharmaceuticals Private Limited, India
8.	Indchemie Health Specialities Private Limited, India
9.	Alkem Laboratories Corporation, Philippines
10.	Alkem Pharma GmbH, Germany
11.	S & B Holdings B.V., Netherlands
12.	Ascends Laboratories SDN BHD., Malaysia
13.	Ascends Laboratories SpA, Chile
14.	Alkem Laboratories Korea Inc, Korea
15.	Pharmacor Ltd., Kenya
16.	The PharmaNetwork, LLP, Kazakhstan
17.	Ascend Laboratories (UK) Ltd., UK
18.	Ascend Laboratories LLC, USA
19.	Ascend Laboratories Ltd., Canada
20.	Alkem Foundation



**ALKEM LABORATORIES LIMITED**

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

**Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31 December 2017**

(₹ in Million except per share data)

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2017 Unaudited	30.09.2017 Unaudited	31.12.2016 Unaudited	31.12.2017 Unaudited	31.12.2016 Unaudited	31.03.2017 Audited
1 Revenue from Operations	17,404.7	18,649.4	14,819.2	49,179.5	46,011.0	58,525.0
2 Other Income	245.8	240.1	254.0	780.8	874.0	1,120.1
3 <b>Total Income (1) + (2)</b>	<b>17,650.5</b>	<b>18,889.5</b>	<b>15,073.2</b>	<b>49,960.3</b>	<b>46,885.0</b>	<b>59,645.1</b>
4 <b>Expenses</b>						
(a) Cost of materials consumed	4,394.6	2,860.6	3,716.1	11,489.0	10,813.4	14,493.2
(b) Purchases of stock-in-trade	3,528.0	1,854.1	2,167.8	7,848.3	8,286.7	10,618.1
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,658.7)	2,366.2	(479.0)	(368.6)	(1,492.7)	(2,896.0)
(d) Employee benefits expense	3,113.7	3,078.0	2,710.1	8,929.6	7,753.6	10,038.5
(e) Finance costs	144.8	178.5	117.2	448.9	337.1	451.6
(f) Depreciation and amortisation expense	375.0	345.7	263.7	1,027.0	748.0	1,011.7
(g) Other expenses	4,429.0	3,885.9	4,023.0	12,134.8	12,153.1	16,281.7
<b>Total Expenses</b>	<b>14,326.4</b>	<b>14,569.0</b>	<b>12,518.9</b>	<b>41,509.0</b>	<b>38,599.2</b>	<b>49,998.8</b>
5 <b>Profit before exceptional item and tax (3) - (4)</b>	<b>3,324.1</b>	<b>4,320.5</b>	<b>2,554.3</b>	<b>8,451.3</b>	<b>8,285.8</b>	<b>9,646.3</b>
6 <b>Exceptional item</b>	-	-	-	-	-	-
7 <b>Profit before tax (5) - (6)</b>	<b>3,324.1</b>	<b>4,320.5</b>	<b>2,554.3</b>	<b>8,451.3</b>	<b>8,285.8</b>	<b>9,646.3</b>
8 <b>Tax expense / (Credit)</b>						
Current tax	918.2	958.2	(798.4)	2,303.0	652.4	2,452.8
Deferred tax	597.2	87.9	990.1	427.4	(43.7)	(1,853.2)
<b>Total Tax expense</b>	<b>1,515.4</b>	<b>1,046.1</b>	<b>191.7</b>	<b>2,730.4</b>	<b>608.7</b>	<b>599.6</b>
9 <b>Net Profit for the period (7) - (8)</b>	<b>1,808.7</b>	<b>3,274.4</b>	<b>2,362.6</b>	<b>5,720.9</b>	<b>7,677.1</b>	<b>9,046.7</b>
10 <b>Other Comprehensive Income (net of tax)</b>						
Items that will not be reclassified to profit or loss	27.7	(10.9)	(18.7)	12.3	(89.6)	(64.5)
Income tax relating to items that will not be reclassified to profit or loss	(9.6)	3.9	6.4	(4.2)	30.8	22.3
Items that will be reclassified to profit or loss	(203.2)	87.9	99.3	(174.5)	130.0	(189.4)
Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total other Comprehensive Income (net of tax)</b>	<b>(185.1)</b>	<b>80.9</b>	<b>87.0</b>	<b>(166.4)</b>	<b>71.2</b>	<b>(231.6)</b>
11 <b>Total Comprehensive Income for the period (comprising Profit for the period (after tax) and Other Comprehensive Income (net of tax)) (9) + (10)</b>	<b>1,623.6</b>	<b>3,355.3</b>	<b>2,449.6</b>	<b>5,554.5</b>	<b>7,748.3</b>	<b>8,815.1</b>
12 <b>Profit attributable to</b>						
a) Owners of the Company	1,716.4	3,206.6	2,334.0	5,638.6	7,550.2	8,920.3
b) Non-Controlling Interest	92.3	67.8	28.6	82.3	126.9	126.4
13 <b>Other Comprehensive Income attributable to</b>						
a) Owners of the Company	(174.3)	80.4	87.0	(156.6)	71.2	(229.2)
b) Non-Controlling Interest	(10.8)	0.5	-	(9.8)	-	(2.4)
14 <b>Total Comprehensive Income attributable to</b>						
a) Owners of the Company	<b>1,542.1</b>	<b>3,287.0</b>	<b>2,421.0</b>	<b>5,482.0</b>	<b>7,621.4</b>	<b>8,691.1</b>
b) Non-Controlling Interest	<b>81.5</b>	<b>68.3</b>	<b>28.6</b>	<b>72.5</b>	<b>126.9</b>	<b>124.0</b>
15 <b>Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>	<b>239.1</b>
16 <b>Other equity</b>						<b>44,437.3</b>
17 <b>Earnings Per Share of ₹2 each (not annualised for the quarters)</b>						
(a) ₹ (Basic)	14.36	26.82	19.52	47.16	63.15	74.61
(b) ₹ (Diluted)	14.36	26.82	19.52	47.16	63.15	74.61

*[Handwritten Signature]*




**Notes :**

- 1 The above unaudited financial results of the Company were reviewed and recommended by the Audit Committee on 8 February 2018 and subsequently approved by the Board of Directors at its meeting held on 9 February 2018. The figures for the quarter and nine months ended 31 December 2017 have been subjected to limited review by the statutory auditors. The auditors have expressed an unmodified opinion in the limited review report for the quarter and nine months ended 31 December 2017.
- 2 The Group operates in one reportable business segment i.e. "Pharmaceuticals".
- 3 Financial results for the periods presented have been prepared in accordance with Indian Accounting standards ('Ind AS') notified by the Ministry of Corporate Affairs in consultation with the National Advisory Committee on Accounting Standards, under section 133 of the Companies Act, 2013 ('Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the relevant provisions of the Act.
- 4 Post implementation of Goods and Service Tax ("GST") with effect from 1 July 2017 and as per Ind AS 18, Revenue from operations is disclosed net of GST. Revenue from operations for the quarter and nine months ended 31 December 2016 and for the year ended 31 March 2017 included excise duty which is now subsumed under GST. Revenue from operations for the nine months ended 31 December 2017 includes excise duty up to 30 June 2017. Accordingly, revenue from operations for the quarter and nine months ended 31 December 2017 are not comparable with those of the previous periods presented.
- 5 In the United States of America, The Tax Cuts and Jobs Act of 2017 was approved and enacted in to law on 22 December 2017. The law includes significant changes to the U.S. corporate income tax system, including a reduction in Federal corporate tax rate from 35% to 21%. Consequently to this enactment, the Company has re-measured its U.S. deferred tax assets and liabilities based on the new tax law and this resulted in a one-off charge of Rs.448.7 million for the quarter ended 31 December 2017.
- 6 The Board of Directors in its meeting held on 9 February 2018 have declared an interim dividend of ₹ 6 (Rupees six only) per equity share of the face value of ₹ 2 each (300%).
- 7 Previous periods' figures have been regrouped/reclassified, where necessary, to make them comparable with the figures for the current period.

Place: Mumbai  
Dated: 9 February 2018

By Order of the Board  
For Alkem Laboratories Limited

  
B.N. Singh  
Executive Chairman  
DIN: 00760310